Comprehensive Stock Comparison
Compare Evogene Ltd. (EVGN) vs Armata Pharmaceuticals, Inc. (ARMP) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  EVGN | 50.9% revenue growth vs ARMP's 14.2% |
| Quality / Margins | EVGN | -52.3% net margin vs ARMP's -9.3% |
| Stability / Safety |  ARMP | Beta 0.21 vs EVGN's 0.54 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | ARMP | +474.8% vs EVGN's -40.6% |
| Efficiency (ROA) | EVGN | -10.5% ROA vs ARMP's -52.4%, ROIC -102.4% vs -44.2% |
Who Each Stock Is For
Income & stability
ARMPDividend streak 0 yrs, beta 0.21
Growth exposure
EVGNRev growth 50.9%, EPS growth 44.7%, 3Y rev CAGR 109.2%
Long-term compounding (10Y)
ARMP-98.0% 10Y total return vs EVGN's -98.8%
Sleep-well-at-night portfolio
ARMPLower volatility, beta 0.21, current ratio 0.23x
Defensive / Recession hedge
ARMPBeta 0.21, current ratio 0.23x
Business Model
What each company does and how it makes money
Evogene is a computational biology company that uses its proprietary AI-powered platform to discover and develop products across agriculture, human health, and industrial applications. It generates revenue through research collaborations, licensing agreements, and milestone payments from partners—primarily in agriculture (~70% of focus) and human health (~30%). The company's key advantage is its Computational Predictive Biology platform, which leverages big data and machine learning to accelerate product discovery in life sciences with higher precision than traditional methods.
Armata Pharmaceuticals is a clinical-stage biotech company developing targeted bacteriophage therapies to treat antibiotic-resistant bacterial infections. It generates revenue primarily through research collaborations and partnerships — like its Merck deal — while advancing its pipeline of phage-based candidates through clinical trials. The company's key advantage is its proprietary bacteriophage platform technology, which offers a novel approach to targeting specific drug-resistant pathogens.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
EVGN 2ARMP 2EVGN4/6 metricsEVGN5/7 metricsARMP6/6 metricsARMP2/2 metricsEVGN leads in 2 of 6 categories (Financial Metrics, Profitability & Efficiency). ARMP leads in 2 (Total Returns, Risk & Volatility). 1 tied.
Financial Metrics (TTM)
EVGN and ARMP operate at a comparable scale, with $5M and $5M in trailing revenue. Profitability is closely matched — net margins range from -52.3% (EVGN) to -9.3% (ARMP). On growth, ARMP holds the edge at -61.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | EVGNEvogene Ltd. | ARMPArmata Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $5M | $5M |
| EBITDAEarnings before interest/tax | -$13M | -$32M |
| Net IncomeAfter-tax profit | -$3M | -$47M |
| Free Cash FlowCash after capex | -$17M | -$27M |
| Gross MarginGross profit ÷ Revenue | +16.1% | +70.5% |
| Operating MarginEBIT ÷ Revenue | -2.8% | -6.6% |
| Net MarginNet income ÷ Revenue | -52.3% | -9.3% |
| FCF MarginFCF ÷ Revenue | -3.2% | -5.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | -82.1% | -61.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +133.6% | -3.9% |
Valuation Metrics
| Metric | EVGNEvogene Ltd. | ARMPArmata Pharmaceut… |
|---|---|---|
| Market CapShares × price | $7M | $42M |
| Enterprise ValueMkt cap + debt − cash | $5M | $159M |
| Trailing P/EPrice ÷ TTM EPS | -0.29x | -22.19x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.86x | 8.13x |
| Price / BookPrice ÷ Book value/share | 0.32x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), EVGN scores 3/9 vs ARMP's 2/9, reflecting mixed financial health.
| Metric | EVGNEvogene Ltd. | ARMPArmata Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -15.9% | — |
| ROA (TTM)Return on assets | -10.5% | -52.4% |
| ROICReturn on invested capital | -102.4% | -44.2% |
| ROCEReturn on capital employed | -66.5% | -70.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | 0.87x | — |
| Net DebtTotal debt minus cash | -$2M | $117M |
| Cash & Equiv.Liquid assets | $15M | $9M |
| Total DebtShort + long-term debt | $13M | $127M |
| Interest CoverageEBIT ÷ Interest expense | -4.42x | -2.12x |
Total Returns (with DRIP)
A $10,000 investment in ARMP five years ago would be worth $25,857 today (with dividends reinvested), compared to $183 for EVGN. Over the past 12 months, ARMP leads with a +474.8% total return vs EVGN's -40.6%. The 3-year compound annual growth rate (CAGR) favors ARMP at 56.0% vs EVGN's -51.8% — a key indicator of consistent wealth creation.
| Metric | EVGNEvogene Ltd. | ARMPArmata Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -25.8% | +77.0% |
| 1-Year ReturnPast 12 months | -40.6% | +474.8% |
| 3-Year ReturnCumulative with dividends | -88.8% | +279.4% |
| 5-Year ReturnCumulative with dividends | -98.2% | +158.6% |
| 10-Year ReturnCumulative with dividends | -98.8% | -98.0% |
| CAGR (3Y)Annualised 3-year return | -51.8% | +56.0% |
Risk & Volatility
ARMP is the less volatile stock with a 0.21 beta — it tends to amplify market swings less than EVGN's 0.54 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ARMP currently trades 71.1% from its 52-week high vs EVGN's 34.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | EVGNEvogene Ltd. | ARMPArmata Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.54x | 0.21x |
| 52-Week HighHighest price in past year | $2.42 | $16.34 |
| 52-Week LowLowest price in past year | $0.81 | $0.90 |
| % of 52W HighCurrent price vs 52-week peak | +34.6% | +71.1% |
| RSI (14)Momentum oscillator 0–100 | 36.0 | 71.9 |
| Avg Volume (50D)Average daily shares traded | 535K | 49K |
Analyst Outlook
| Metric | EVGNEvogene Ltd. | ARMPArmata Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $9.00 |
| # AnalystsCovering analysts | — | 4 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Mar 26 | Change |
|---|---|---|---|
| Evogene Ltd. (EVGN) | 100 | 7.14 | -92.9% |
| Armata Pharmaceutic… (ARMP) | 100 | 303.72 | +203.7% |
Armata Pharmaceutic… (ARMP) returned +159% over 5 years vs Evogene Ltd. (EVGN)'s -98%. A $10,000 investment in ARMP 5 years ago would be worth $25,857 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Evogene Ltd. (EVGN) | $11M | $9M | -23.5% |
| Armata Pharmaceutic… (ARMP) | $475000.00 | $5M | +989.3% |
Evogene Ltd.'s revenue grew from $11M (2015) to $9M (2024) — a -2.9% CAGR. Armata Pharmaceuticals, Inc.'s revenue grew from $0M (2015) to $5M (2024) — a 30.4% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Evogene Ltd. (EVGN) | -154.7% | -193.7% | -25.2% |
| Armata Pharmaceutic… (ARMP) | -108.6% | -3.7% | +96.6% |
Evogene Ltd.'s net margin went from -155% (2015) to -194% (2024). Armata Pharmaceuticals, Inc.'s net margin went from -109% (2015) to -4% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Evogene Ltd. (EVGN) | -0.68 | -2.89 | -325.0% |
| Armata Pharmaceutic… (ARMP) | -278.6 | -0.52 | +99.8% |
Evogene Ltd.'s EPS grew from $-0.68 (2015) to $-2.89 (2024). Armata Pharmaceuticals, Inc.'s EPS grew from $-278.60 (2015) to $-0.52 (2024).
Chart 5Free Cash Flow — 5 Years
Evogene Ltd. generated $-20M FCF in 2024 (+20% vs 2021). Armata Pharmaceuticals, Inc. generated $-39M FCF in 2024 (-58% vs 2021).
EVGN vs ARMP: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is EVGN or ARMP a better buy right now?
Analysts rate Armata Pharmaceuticals, Inc. (ARMP) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — EVGN or ARMP?
Over the past 5 years, Armata Pharmaceuticals, Inc. (ARMP) delivered a total return of +158.6%, compared to -98.2% for Evogene Ltd. (EVGN). A $10,000 investment in ARMP five years ago would be worth approximately $26K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ARMP returned -98.0% versus EVGN's -98.8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — EVGN or ARMP?
By beta (market sensitivity over 5 years), Armata Pharmaceuticals, Inc. (ARMP) is the lower-risk stock at 0.21β versus Evogene Ltd.'s 0.54β — meaning EVGN is approximately 156% more volatile than ARMP relative to the S&P 500.
04Which has better profit margins — EVGN or ARMP?
Evogene Ltd. (EVGN) is the more profitable company, earning -193.7% net margin versus -365.6% for Armata Pharmaceuticals, Inc. — meaning it keeps -193.7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EVGN leads at -255.4% versus -820.2% for ARMP. At the gross margin level — before operating expenses — EVGN leads at 39.8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — EVGN or ARMP?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is EVGN or ARMP better for a retirement portfolio?
For long-horizon retirement investors, Armata Pharmaceuticals, Inc. (ARMP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.21)). Both have compounded well over 10 years (ARMP: -98.0%, EVGN: -98.8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between EVGN and ARMP?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.